Atyr Pharma Inc. (LIFE) Downgraded by Zacks Investment Research
Atyr Pharma Inc. (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
Several other research firms have also recently weighed in on LIFE. Citigroup Inc. boosted their price objective on shares of Atyr Pharma from $3.00 to $4.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 16th. JPMorgan Chase & Co. dropped their price objective on shares of Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, August 11th. Finally, BMO Capital Markets set a $8.00 target price on shares of Atyr Pharma and gave the company a “hold” rating in a research report on Thursday, October 6th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $6.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/atyr-pharma-inc-life-downgraded-by-zacks-investment-research.html
Shares of Atyr Pharma (NASDAQ:LIFE) opened at 2.89 on Wednesday. The firm’s market capitalization is $68.55 million. The company has a 50-day moving average price of $3.12 and a 200 day moving average price of $3.24. Atyr Pharma has a 52-week low of $2.48 and a 52-week high of $13.26.
Atyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.06. Analysts expect that Atyr Pharma will post ($2.56) EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP purchased a new stake in Atyr Pharma during the second quarter worth approximately $101,000. A.R.T. Advisors LLC boosted its stake in Atyr Pharma by 88.8% in the second quarter. A.R.T. Advisors LLC now owns 39,143 shares of the company’s stock worth $108,000 after buying an additional 18,410 shares in the last quarter. Bridgeway Capital Management Inc. purchased a new stake in Atyr Pharma during the second quarter worth approximately $133,000. Jackson Park Capital LLC purchased a new stake in Atyr Pharma during the second quarter worth approximately $183,000. Finally, Emerald Acquisition Ltd. purchased a new stake in Atyr Pharma during the second quarter worth approximately $206,000. Institutional investors own 44.75% of the company’s stock.
Atyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.